Search Results
Aug 19, 2026, 16:32 ET 亞裔名人堂在創辦人晚宴上擴大社區影響力
Lee夫婦由同為名人堂年度人物的 Omar Lee 與 Christine Lee夫婦頒授 2026年度人物（Class of 2026），宣布其正式進入亞裔名人堂。11月5日在洛杉磯將舉行年度人物典禮。艾美獎得主、KOMO News主播 Molly Shen 擔任當日晚宴司儀。曾任 MG2 執行長（CEO） 的 Jerry Lee 與妻子 Charlene Lee成為年度人物凸顯兩人長期以來對慈善事業及西雅圖社區領導工作的投入。值得注意的是，Jerry Lee 是當年名人堂四名創始委員之一，曾參與構思及建立名人堂最初構想。Jerry 與 Charlene Lee表示，他們作為華人，很感謝能進入亞裔名人堂。他的許多慈善精神都來自父母影響。他的父母白手起家，養大
More news about: Asian Hall of Fame
Aug 19, 2026, 15:37 ET Asian Hall of Fame Amplifies Impact at Founders Gala
The induction of former MG2 CEO Jerry Lee and his wife Charlene highlighted their longstanding commitment to philanthropy and community leadership in Seattle. Jerry Lee is among
More news about: Asian Hall of Fame
Aug 19, 2026, 09:04 ET Superbrewed Food Launches Thryvia™, the First Shelf-Stable Protein-Derived Postbiotic for Digestive and Immune Health Formulations
bars, foods, and beverages—including shelf-stable and UHT-processed formats—as well as pet nutrition. At a typical inclusion rate of approximately 200 mg per serving, Thryvia enables flexible product development without the viability-management requirements associated with live probiotics."Consumers
More news about: Superbrewed Food Inc.
Aug 19, 2026, 09:02 ET PEET'S REVEALS RETURN OF THE COLD BREW PASS FOR NATIONAL COFFEE DAY ALONG WITH PUMPKIN AND APPLE AS FLAVOR FOCUS IN FALL MENU
Available iced with or without Vanilla Dream Top.Sparkling Green Apple Energy: Juicy Granny Smith apple purée, club soda, and approximately 80mg of plant-derived caffeine, plus L-theanine and 100% of the daily recommended value of Vitamin B-12.Vine & Walnut Autumn Blend: An
More news about: PEET'S COFFEE INC.
Aug 19, 2026, 06:00 ET FLRT Debuts First-Ever Flavor Innovation, Apple Bottoms Up, Just in Time for Fall
lineup.Each can of FLRT is as beautiful on the inside as it is on the outside:Formulated with green tea, guayusa, ginseng and 200 mg of caffeine to help accelerate metabolism, increase energy, improve focus and support everyday wellness.Features biotin, zinc and vitamins A,
More news about: FLRT
Aug 19, 2026, 02:03 ET Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
2025.[3] Abilify long-acting injectable (LAI) franchise comprises the following products: Abilify Maintena®, Abilify Maintena® 960 mg, and Abilify Asimtufii®.[4] Comparatives were restated to reflect the final purchase-price allocation for the Longboard business
More news about: H. Lundbeck A/S
Aug 19, 2026, 01:59 ET Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
2025.[3] Abilify long-acting injectable (LAI) franchise comprises the following products: Abilify Maintena®, Abilify Maintena® 960 mg, and Abilify Asimtufii®.[4] Comparatives were restated to reflect the final purchase-price allocation for the Longboard business
More news about: H. Lundbeck A/S
Aug 18, 2026, 21:00 ET Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
high CLDN18.2 expression (IHC 2+ ≥ 20%) in the 2.4 mg/kg dose cohort, the objective response rate (ORR) was 42.4% (14/33) and the disease control rate (DCR) was 90.9% (30/33), with a median overall survival (mOS) of 12.85 months. In the 1.8 mg/kg dose cohort, the ORR was 46.7% (14/30), the
More news about: Antengene Corporation Limited
Aug 18, 2026, 11:00 ET Novo Nordisk obtiene en México la primera aprobación en América Latina para semaglutida oral 25 mg (Wegovy® tabletas) marcando una nueva era en el manejo oral del peso
Inyección de semaglutida 2.4 mg y 7.2 mg, aprobada para el control crónico del peso en adultos con obesidad o sobrepeso con una o más comorbilidades relacionadas con el peso, según se indica en la información de prescripción aprobada.Semaglutida oral 25 mg, aprobada en ciertos mercados
More news about: Novo Nordisk
Aug 18, 2026, 10:00 ET ALP Introduces the Frontier Collection: Three New Flavors and a Cinematic Campaign Inspired by the American West
view. Available exclusively through ALP's direct-to-consumer platform, the collection also introduces new 4mg and 8mg nicotine strengths, giving adult consumers finer control across ALP's full 3–12mg range.To bring the collection to life, ALP partnered with creator Dave '
More news about: ALP Supply Co. LLC
Aug 18, 2026, 08:00 ET Kedrion Biopharma Announces the Extension of a U.S. Agreement with Grifols to Support Long-Term and Continued Access to GAMMAKED®
of pre-existing renal insufficiency or risk factors for renal insufficiency, administer GAMMAKED at the minimum infusion rate practicable [less than 8 mg/kg/min (0.08 mL/kg/min)].Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia: Hyperproteinemia, increased serum viscosity, and
More news about: Kedrion Biopharma
Aug 18, 2026, 06:00 ET Smoothie King Introduces the First-Ever Delicious and Nutritious GLP-1 Support Pumpkin Smoothie
GLP-1 friendlyPower Meal® Pumpkin - 20+g protein, meal replacementCoffee High Protein Pumpkin - 31+g protein, 83mg caffeineSlim-N-Trim® Pumpkin - 13+g protein, 0g added sugarD-Lite® Pumpkin - 12+g proteinVegan Pumpkin -
More news about: Smoothie King
Aug 17, 2026, 14:15 ET Harvey Unleashes the BABY GYRO AIR G-200H: 550 Air Watts of Shop-Vacuum Fury -- With No Filter Bags Required
RPMManual Air-Pulse Filter Cleaning restores airflow in seconds99.35% Filtration of 0.3–0.5 μm particles; emissions as low as 0.05 mg/m³Noise levels down to 75 dB with a refined sound signature — power without the punishing whine90° Lay-Flat Truck-Bed Mobility with
More news about: Harvey Industries International, Inc.
Aug 17, 2026, 11:58 ET Lupin Announces Approval from U.S. FDA for Pitolisant Tablets
approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.
More news about: Lupin Pharmaceuticals, Inc.
Aug 17, 2026, 10:32 ET Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarrhythmic Agents | DelveInsight
in mid-2026.In February 2026, Cytokinetics announced that the European Commission (EC) has approved aficamten (MYQORZO), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic oHCM in adult patients.Hypertrophic Cardiomyopathy Epidemiology SegmentationThe
More news about: DelveInsight Business Research, LLP
Aug 17, 2026, 07:13 ET USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
New Clear Protein + Creatine Mix combines three active nutrition essentialswith 10 g of protein, 5 g of creatine, and 600+ mg of electrolytes in just 50calories SALT LAKE CITY, Aug. 17, 2026
More news about: USANA
Aug 17, 2026, 00:23 ET Duesenberg SSJ Special Speedster Named Best of Show at the 75th Pebble Beach Concours d'Elegance
PhaetonThe NB Center for American Automotive Heritage, Allentown, PennsylvaniaDean Batchelor Trophy1954 MG R2 Ken Miles "Flying Shingle" SpecialBill Hart, Carnation, WashingtonElegance in Motion Trophy1938 Alfa
More news about: Pebble Beach Concours d'Elegance
Aug 14, 2026, 08:08 ET The Law Offices of John David Hart: Texas Woman Sues Victory Medical Center Pharmacy, an Austin Compounding Pharmacy, After Hospitalization Following IV Infusion From Recalled Lot
August 5, 2026, Victory Medical Center Pharmacy announced a voluntary nationwide, patient-level recall of certain lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials, including Lots 1981940, 1980571, and 1984345. According to the recall announcement posted by the U.S. Food and Drug Administration,
More news about: The Law Offices of John David Hart
Aug 13, 2026, 16:10 ET cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026
additional M&A opportunities, continued investment in product development and clinical/regulatory initiatives, including our recent self-GRAS at 200mg per day, and incremental supply-chain and state-level compliance costs, including higher inventory reserves. The Company also identified additional supply-chain
More news about: cbdMD, Inc.
Aug 13, 2026, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
safety of intravitreal KSI-501 5 mg compared with intravitreal aflibercept 2 mg in patients with visual impairment secondary to center-involved DME. Approximately 910 patients, treatment-naïve or previously treated, will be randomized 5:3:5 to one of three arms: (A) KSI-501 5 mg every 8 weeks, with monthly
More news about: Kodiak Sciences Inc.
Aug 13, 2026, 16:00 ET Four Vials Bought at Brooklyn Smoke Shop Fail Identity Testing
any sample; purity & quantity were indeterminateThe purchase included two INDR Labs-branded vials labeled Retatrutide 10 mg and two labeled NAD+ 500 mg. Peptide Critic purchased the products from Smoker's World in Brooklyn and submitted all four vials to Analytical Formulations, Inc. for
More news about: Peptide Critic
Aug 13, 2026, 10:31 ET Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
Research Collaboration (EMBARC) announced at the World Bronchiectasis Conference (WBC 2026) its planned collaboration with Insmed to assess brensocatib 25 mg, an oral and reversible dipeptidyl peptidase-1 (DPP-1) inhibitor. In May 2026, Infex Therapeutics reported encouraging findings from its
More news about: DelveInsight Business Research, LLP
Aug 13, 2026, 08:05 ET Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
harness the body's natural machinery to selectively degrade, rather than inhibit, disease-causing proteins. The recommended dosage of VEPPANU is 200 mg taken orally once daily. VEPPANU is immediately available through Rigel's network of specialty distributors and specialty pharmacies in the United States
More news about: Rigel Pharmaceuticals, Inc.
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
presentations and publication of the SENTRY results in the Journal of Clinical Oncology.Continue enrolling patients into the 40 mg cohort of the Phase 2 SENTRY-2 trial (
More news about: Karyopharm Therapeutics Inc.
Aug 12, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic
More news about: Neurocrine Biosciences, Inc.